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Abstract: (1) Introduction: Dementia is a major public health problem, and Alzheimer’s disease (AD)
is the most frequent subtype. Clarifying the potential risk factors is necessary in order to improve
dementia-prevention strategies and quality of life. Here, our purpose was to investigate the role of
the absence of hedonic tone; anhedonia, understood as the reduction on previous enjoyable daily
activities, which occasionally is underdetected and underdiagnosed; and the risk of developing AD
in a cognitively unimpaired and non-depressed population sample. (2) Method: We used data from
the Zaragoza Dementia and Depression (ZARADEMP) project, a longitudinal epidemiological study
on dementia and depression. After excluding subjects with dementia, a sample of 2830 dwellers aged
≥65 years was followed for 4.5 years. The geriatric mental state examination was used to identify
cases of anhedonia. AD was diagnosed by a panel of research psychiatrists according to Diagnostic
and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria. A multivariate survival
analysis and Cox proportional hazards regression model were performed, and the analysis was
controlled by an analysis for the presence of clinically significant depression. (3) Results: We found a
significant association between anhedonia cases and AD risk in the univariate analysis (hazard ratio
(HR): 2.37; 95% CI: 1.04–5.40). This association persisted more strongly in the fully adjusted model.
(4) Conclusions: Identifying cognitively intact individuals with anhedonia is a priority to implement
preventive strategies that could delay the progression of cognitive and functional impairment in
subjects at risk of AD.
Keywords: anhedonia; Alzheimer’s disease; psychopathology; risk factor; neuropsychiatry;
community study
1. Introduction
Dementia constitutes a serious public health challenge worldwide. By 2030, 82 million
people are expected to develop dementia, and that number is expected to reach over
152 million in 2050 [1,2]. Cognitive impairment is a core symptom, along with the presence
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of functional impairment in the context of a gradual and progressive clinical evolution [3].
In this context, Alzheimer’s disease is the most frequent subtype of dementia, and it has
a huge impact not only on the patient (institutionalization, risk of mortality, etc.) and
the caregivers (such as psychiatric complications) [4,5], but also on the socioeconomic
dimension [1,2]. The lack of an effective treatment highlights the need for the identification
of potential psychopathological risk factors, and the improvement of prevention strategies
to decrease its incidence and improve quality of life. Nevertheless, longer periods of
observation are needed, with a sufficient frame of time to reduce the risk of AD, so further
investigations are fundamental.
The association between clinically significant depression and dementia is well
known [6,7]. This is specifically true for severe and major episodes [8], with severe cases of
depression being four times at greater risk of Alzheimer’s disease (AD) compared with
subjects without depression [9]. There are two main clinical manifestations to diagnose a
major depressive disorder: hypothymia and/or anhedonia [3]. Hypothymia is understood
as a decrease in the baseline holothymic state, which includes the affective tone and
emotional reactivity. Anhedonia is conceptualized as the presence of a reduction or lack of
interest or enjoyment in previously pleasurable projects, which could be understood as a
type of negative non-cognitive symptom [10] or a mood-related one.
Previous studies [11–16] suggest that anhedonia could be either a potential preclinical
sign of cognitive decline or a psychopathological risk factor of dementia. However, the
potential association of depression-spectrum symptoms and Alzheimer’s disease is still
unknown. Furthermore, the heterogeneity of the definition of anhedonia across different
studies has led to mixed results.
In the Zaragoza Dementia and Depression (ZARADEMP) project, a longitudinal
epidemiological study of dementia and depression conducted in community-dwelling
older adults, the authors found that anhedonia was frequently observed among cases of
Alzheimer’s disease (46.8% vs. 2.5% in non-demented participants) [10,11]. Other epidemi-
ological studies suggest that the presence of anhedonia implies a two-times greater risk
of mild cognitive impairment and, remarkably, this symptom increases the probability of
dementia by a factor of five [15], particularly Alzheimer’s disease [16]. These results may be
supported by studies showing a link between apathy and amyloid burden in mild cognitive
impairment [12], and by those reporting an association of “apathy-anhedonia” symptoms
and hypometabolism in certain brain regions and hippocampal volume reductions [13],
with a probable proinflammatory role of the microglia [14].
Although a link between anhedonia and the risk of dementia is strongly suggested [15,16],
further epidemiological studies with representative samples of cognitively intact people
are needed. Thus, our purpose was to investigate the relationship between anhedonia and
the risk of Alzheimer’s disease in cognitively intact community-dwelling elderly people
without depression.
2. Materials and Methods
2.1. Sample
We used data from the ZARADEMP project [17,18], a longitudinal population-based
study conducted in Zaragoza, Spain. The main objective was to estimate the incidence
and risk factors for dementia and depression in adults aged 55 years or older. Further
information about objectives and design has been published previously [18].
Briefly, a random sample of community-dwelling older people was drawn from the
Spanish official census list of 1991, which included institutionalized individuals and was
stratified with proportional allocation by age and gender. The refusal rate was 20.5%;
4803 individuals participated at baseline (Wave I started in 1994). Individuals with all-
cause dementia were excluded from the two follow-up waves (second wave in 1997 and
third wave in 1999) because we were interested in cognitively intact individuals, so that
stringent criteria were applied. Additionally, subjects with “subsyndromal” dementia at
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baseline, according to the Geriatric Mental State (GMS) Automated Geriatric Examination
for Computer Assisted Taxonomy package (AGECAT) criteria [19], were also excluded.
For ease of comparison with the existing literature, we focused on participants aged
65 years and older. Additionally, we focused on those participants who participated both
at baseline and in the second wave, resulting in a final sample of 1642 participants for
statistical analysis [20].
2.2. Procedure
In phase I, the ZARADEMP interview was conducted by well-trained and regularly
supervised lay-interviewers at each participant’s residence, or in hospital if this option
was preferred.
This interview incorporated standardized and validated Spanish versions of the
following international instruments: Mini-Mental State Examination (MMSE) [21], Geri-
atric Mental State (GMS) [19], and History and Aetiology Schedule (to asses psychiatric
history) [22], and the Katz Index [23] and Lawton and Brody Scale [24] (to assess basic
and instrumental activities of daily living (ADLs), respectively). The European Stud-
ies of Dementia (EURODEM) Risk Factors Questionnaire [19,25] was used to consider
medical history.
In phase II, a trained research psychiatrist reassessed participants to confirm the
suspected clinical diagnosis of dementia and/or depression. The validity of this approach
has been established [26]. A similar procedure was implemented in the second and third
(2.5 and 4.5 years later, respectively), in which interviewers were not aware of the results of
the baseline interview described beforehand. A more detailed account of the methods has
been published elsewhere [17].
2.3. Ethics
The Ethics Committee of Research of Aragón (CEICA) approved the project in accor-
dance with Spanish law. The Declaration of Helsinki principles [27] of written informed
consent, confidentiality, and privacy were maintained throughout the project.
2.4. Clinical Measurements
2.4.1. Alzheimer’s Disease Assessment and Diagnosis
At the end of the baseline assessment, identified “cases” of dementia and “subcases”
of dementia (according to GMS-criteria) were excluded from the follow-up waves. Partici-
pants were considered “probable cases” on the basis of a GMS threshold “global” score
(1/2) and/or MMSE (23/24) standard cutoff points.
A panel of four research psychiatrists made the final diagnoses of cases of demen-
tia. The validity of this diagnostic process has also been proven [26]. Variables in the
ZARADEMP interview were operationalized to conform to the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition (DSM-IV) [3] criteria, used to diagnose cases.
Agreement by at least three out of the four psychiatrists was necessary for a diagnosis of
“incident” dementia and “type of dementia” (e.g., AD or vascular dementia).
To document the accuracy of the panel of psychiatrists, detected cases were invited
to a hospital diagnostic work-up, which included a neurological examination and neu-
roimaging. For the purposes of this paper, we focused on AD cases. Nacional Institute of
Neurological and Communicative Disorders and Stroke-Alzheimer´s Disease and Related
Disorders Association (NINCDS-ADRDA) criteria were applied to diagnose AD.
2.4.2. Anhedonia Assessment and Diagnosis
Geriatric Mental State (GMS) is a semi-structured standardized clinical interview for
assessing the mental state of elderly people [19]. It includes melancholic items, such as the
symptom of anhedonia, and a computerized diagnostic program, namely AGECAT. This
consists of a set of computer algorithms to analyze the GMS data, which was applied to
Int. J. Environ. Res. Public Health 2021, 18, 1370 4 of 12
reach the psychiatric diagnosis [19,28]. The reliability and validity of the Spanish version
of the GMS-AGECAT procedure has been reported elsewhere [28].
For the purpose of this study, the symptom of anhedonia, which appears in the
DSM-IV and in the International Classification of Diseases (ICD-10) as a melancholic or a
negative-non-cognitive clinical manifestation, was operationalized using the information
from the GMS through the following questions: Do you take pleasure in anything? What do
you like doing lately? Has there been any change? We followed standard GMS procedures
to use binary variables throughout the calculation process. To this end, we recorded
“0” (when the symptom was absent), and scores “1” (symptom present, but mild or not
frequent) and “2” (symptom frequent and/or severe) were collapsed.
2.5. Covariates
The potential confounders assessed at baseline included sociodemographic character-
istics (age, gender [29], educational level, marital status [30–32], and living alone), medical
risk factors based on the medical history obtained using the EURODEM Risk Factors Ques-
tionnaire [33] (vascular disease [34], hypertension, and diabetes), cognitive state (MMSE
score), functional disability (ADL [35]), body mass index (BMI), and clinically significant
depression [9,36,37].
2.6. Statistical Analysis
Differences between baseline characteristics according to anhedonia status were as-
sessed using two-tailed chi-square tests on categorical data, and differences in variables
with approximately normal distributions were assessed using a two-tailed t-test. Standard
procedures were used to calculate the incidence rate and incidence rate ratio (IRR).
The follow-up period ended in the second follow-up examination (third wave) for
the cognitively intact individuals, at the date of invitation for refusals, at the date of
moving away or death (based on actual data from the Civil Registry, Padrón Municipal de
Habitantes de Zaragoza), or at the time of onset of dementia for cases. The time of onset of
dementia was estimated to be the time from baseline to the midpoint between diagnosis
and the previous examination.
We built Kaplan–Meier survival curves according to the anhedonia status. The proba-
bility of AD-free survival across groups was assessed by means of the Tarone-Ware test.
We used the Cox proportional hazards regression model to calculate the risk of
participants who had the psychopathological symptom of anhedonia (cases), compared
with those without this clinical manifestation (no cases), for experiencing AD, and with age
as timescale with delayed entry [38]. To explore the mechanisms explaining the association
between anhedonia and the risk of developing AD, we used a series of models in which
we gradually controlled for the potential modifiers previously mentioned. We confirmed
the assumption of proportional hazards by means of the Therneau and Grambsch test [39].
Statistical analyses were conducted using R software (http://www.r-project.org)
(R Foundation for Statistical Computing, Vienna, Austria), with the epiR package to
analyze epidemiologic data, and the survival and survminer packages for the survival
analyses.
3. Results
Our final sample included 2830 older adults free of dementia at baseline (median
4.4 years; interquartile range: 2.8–4.9 years). During the follow-up period (4.5 years),
1565 (55.3%) were non-incident AD cases, 77 (2.7%) were incident AD cases, 44 (1.5%) were
incident cases of other dementias, 605 (21.4%) died, and 539 (19%) were lost (by refusal
to take part, changing residence, or being impossible to contact; Figure 1). Those lost or
dead during follow-up were older (p < 0.001) and more likely to be illiterate than those
re-evaluated; the MMSE scores were also lower among those lost or dead (p < 0.001; data
not shown).
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Figure 1. Zaragoza Dementia and Depression (ZARADEMP) project study flow chart. Notes: AD—Alzheimer’s disease.
Table 1 shows the sociodemographic characteristics at baseline according to the AD
incidence status. Participants with incident AD were significantly older, were more likely
to be female, formerly married, or to have a lower educational level, and were more likely
to have depression, to perform worse cognitively, to have anhedonia, and to have more
functional disabilities than participants without AD.
The crude comparison of the survival curves according to anhedonia status (Figure 2)
revealed a more favorable survival probability in the no case group (Tarone-Ware test;
p = 0.003). In fact, the age survival median was 96.3 years (95% CI: 94.2–100) for no
case participants, significantly higher than 91.1 years (95% CI: 89.5–100) for the cases
of anhedonia.
Table 2 shows a significant association between “anhedonia cases” at baseline and AD
risk. Compared with no cases, the proportion of incident cases and the incidence rate of
AD were higher among anhedonia cases (IRR = 2.5; p-value = 0.021). Table 2 also shows the
results of the Cox regression analysis for the risk of AD associated with anhedonia status.
The risk of AD was almost 2.5-fold higher in anhedonia cases compared with no cases
when the socio-demographics factors were controlled for (hazard ratio (HR): 2.37; 95% CI:
1.04–5.40). This association persisted or was slightly higher in the fully adjusted model.
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Table 1. Baseline characteristics according to incident AD status.
Follow-Up AD Status
Variables Non-Incident AD(N = 1565)
Incident AD
(N = 77) p-Value
Socio-demographic characteristics
Age (years) 73.4 (6.5) 84.1 (6.6) <0.001
Female sex 874 (55.8%) 55 (71.4%) 0.010
Education (years) 7.6 (3.9) 5.7 (3.5) <0.001
Marital status
(ref. single) <0.001
Married/in couple 1001 (63.9%) 23 (29.9%)
Formerly married 409 (26.1%) 53 (68.8%)
Psychopathological risk factors
Depression 110 (7%) 10 (13%) 0.082
Anhedonia 48 (3%) 7 (9%) 0.011
Behavioural risk factors
BMI 27.1 (6.3) 26.1 (5.1) <0.001
Vascular risk factors
Diabetes 192 (12.2%) 8 (10.4%) 0.770
Hypertension 1116 (71.3%) 49 (63.6%) 0.181
Previous vascular disease 110 (7%) 5 (6.5%) 0.304
Functional and cognitive status
Basic ADLs 69 (4.4%) 13 (16.9%) <0.001
Instrumental ADLs 131 (8.4%) 32 (41.6%) <0.001
MMSE score 30.8 (2.8) 27.4 (2.9) <0.001
Notes: AD (Alzheimer Disease); ADLs: Activities of Daily Living; BMI: Body Mass Index. Data are given as mean
(standard deviation) or frequency (%).
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Notes: AD—Alzheimer’s disease; IR—incidence rate; IRR—incidence rate ratio; HR—hazard ratio. Reported HR of AD is related to no
cases. CIs and p-values related to HR were from a “normal approximation” of Wald’s χ2 test with 1 df. Model 1: included anhedonia
plus terms for socio-demographic characteristics (sex, years of education, and marital status). Model 2: included additional terms for
vascular risk factors (body mass index, previous vascular disease, hypertension, and diabetes), depression, disability, and cognitive status
at baseline (MMSE).
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4. Discussion
Our observations suggest that the appearance of anhedonia in cognitively intact and
non-depressed older people increases the risk of developing AD by 2.5 times, compared
with those without anhedonia and after controlling for the effect of sociodemographic
factors. With the aim of uncovering the multicausality and complexity of Alzheimer’s
disease, this is the first study to report a significant association between the presence of
anhedonia (independent of a depressive disorder) and risk of AD.
Studies focusing on anhedonia as part of a mood disorder suggest that anhedonia
predicts a significant worse clinical prognosis in subjects with acute coronary syndrome [40],
where it doubles the risk of suffering from another episode again [41,42]. Previous literature
has also suggested anhedonia to be a predictor of death in patients with systolic heart
failure [43], patients undertaking a coronary stent implantation [44], and community-
dwelling adults with type-2 diabetes [45].
Int. J. Environ. Res. Public Health 2021, 18, 1370 8 of 12
Literature about anhedonia as a symptom (outside the context of a mood episode) has
shown that subjects with anhedonia have a higher risk of cardiovascular diseases [16,40–44],
type-2 diabetes [46], and mild cognitive impairment (MCI) [15].Moreover, some experimen-
tal works based on animal models suggest that anhedonia may increase risk of AD [47–49].
The presence of the symptom of anhedonia without a major depressive disorder
was associated with a six-times higher risk of conversion to AD in individuals with MCI.
Furthermore, this association has not been found in depressed people with an appropri-
ate hedonic tone [16]. A similar study conducted in the Korean Longitudinal Study on
Cognitive Aging and Dementia (KLOSCAD), a prospective multicenter cohort study in
adults aged 60 years or older [50], found that non-demented and non-clinically depressed
participants with anhedonia were at a five-times greater risk of global dementia than those
with an appropriate hedonic tone [15]. This study, though, did not report the specific risk
by subtypes of dementia (e.g., AD).
Our study is the first to analyze the association between anhedonia and Alzheimer’s
disease in cognitively unimpaired elderly people without clinical depression. In contrast
with previous studies [45] that assessed anhedonia by means of self-reported question-
naires, we used a semi-structured standardized ZARADEMP clinical interview where
GMS-AGECAT was included, which is specific for a psychogeriatric population. Control-
ling for clinically significant depression and the use of international and reliable clinical
instruments should increase the confidence in our results, especially in those concerning
the independent role of anhedonia from depression [15,16] as a genuine risk factor of AD.
Some specific neurobiological pathways might be involved in the association between
anhedonia and AD. Firstly, we reported some evidence that found that anhedonia increases
the risk of diabetes and cardiovascular disease; both have been consistently associated
with an increased risk of AD [45]. However, we controlled our analysis for those risk
factors, and the association between anhedonia and incident AD were independent of them.
Otherwise, loss of pleasure is related with reward-related deficits [51], and different brain
structures have been suggested to be involved, such as the prefrontal cortex (ventromedial
and orbitofrontal) [52], dorsal and ventral striatum [53] (nucleus accumbens) [54–56], area
tegmental ventral, amygdala [57], habenula [58], primarily mediated by dopaminergic
and glutamatergic systems [51,59,60]. From an experimental approach, a “vicious cycle
of stress” is described [47], with anhedonia being a source of emotional discomfort in the
context of vulnerability to stress [61]. This clinical manifestation is capable of reducing
the hippocampal volume [12,13] and disrupting microglia function through the activation
of the brain neuroinflammation (a cytokine cascade and oxidative stress) [14,48], which
determines an increased risk of developing AD [49]. In turn, neuroinflammation might
increase the severity of anhedonic symptomatology [47].
It is still unknown if anhedonia is a genuine risk factor of AD or rather an incipient
prodromal symptom of AD. As we were primarily interested in the implications of an-
hedonia in a cognitively intact sample, we excluded those cases with dementia or mild
cognitive deficits at baseline. Additionally, in order to study the role of anhedonia out-
side the context of a major depressive episode, we controlled our analysis for clinically
significant depression at baseline, as well as a history of depression and/or treatment with
antidepressants. Thus, our findings seem to suggest that anhedonia as a symptom might
be a potential independent risk factor of AD.
Nevertheless, anhedonia could be a symptom of subsyndromal or minor depression,
which consists of depressive symptoms that do not meet the criteria for clinically significant
or major depression. Subsyndromal depression has been associated with poorer outcomes
and an increased dementia global risk [8]. Anhedonia could also be a symptom of apathy
syndrome, which has consistently been found to be a risk factor of progression to dementia
in different clinical samples [62]. However, anhedonia refers specifically to the affective
component of apathy, which could respond better to treatment with antidepressants than
behavioral apathy. Future studies could attempt to uncover to a better understanding of
the context of anhedonia as a risk factor of AD. Furthermore, they should also determine
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if the detection of anhedonia in non-depressed subjects and its treatment could have a
preventive effect on AD risk.
Some of the limitations of this study are attributable to a relatively short follow-up
period. Longer periods of time might be needed to clarify whether anhedonia is a genuine
risk factor of dementia or rather a prodromal symptom. We did not analyze biochemical
markers in the blood, serum, or cerebrospinal fluid, because our study has an epidemi-
ological basis and our main objective was to document the association between diverse
risk factors and incident cases of dementia in the elderly population, using several instru-
ments specific for psychogeriatric dwellers [18]. Nevertheless, biochemical markers might
have helped us to understand the different pathophysiological and psychopathological
pathways underlying mechanisms between anhedonia and AD a bit better, so further
research is needed. In addition, it is difficult to make a comparison between our results
and those of other epidemiological studies, because of the diverse assessment instruments
and definitions of anhedonia [55]. Anhedonia is sometimes not properly operationalized
or considered to be equivalent to a reduction in positive affect or a loss of interest and
hopefulness [43].
5. Conclusions
In conclusion, our study suggests that anhedonia, independent of a mood disorder, is
a probable psychopathological risk factor of AD. Thus, measuring this symptom in daily
clinical practice could provide a helpful, rapid, and easy tool for clinicians to identify
those cases at risk of AD. Those subjects at risk should be kept under observation over
time and offered effective dementia prevention strategies [2,6,37,63,64] in order to prevent
progression to AD.
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